期刊
FRONTIERS IN CHEMISTRY
卷 2, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2014.00087
关键词
ntisense; oligonucleotides; cancer; therapeutics; nanomedicine
资金
- FEDER funds through the Programa Operational Factores de Competitividade-COMPETE
- Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologia [PTDC/CTM-NAN/115124/2009, HMSP-ICT/0020/2010, PEst-C/SAU/LA0002/2013]
- Marie Curie Action of the European Community's Seventh Framework Program [PIEF-GA-2011-300485]
- Fundação para a Ciência e a Tecnologia [PTDC/CTM-NAN/115124/2009, HMSP-ICT/0020/2010, PEst-C/SAU/LA0002/2013] Funding Source: FCT
Under clinical development since the early 90's and with two successfully approved drugs (Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet delivered a clinical drug to the market in the cancer field. Whilst many pre-clinical data has been generated, a lack of understanding still exists on how to efficiently tackle all the different challenges presented for cancer targeting in a clinical setting. Namely, effective drug vectorization, careful choice of target gene or synergistic multi-gene targeting are surely decisive, while caution must be exerted to avoid potential toxic, often misleading off-target-effects. Here a brief overview will be given on the nucleic acid chemistry advances that established oligonucleotide technologies as a promising therapeutic alternative and ongoing cancer related clinical trials. Special attention will be given toward a perspective on the hurdles encountered specifically in the cancer field by this class of therapeutic oligonucleotides and a view on possible avenues for success is presented, with particular focus on the contribution from nanotechnology to the field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据